Inclusion Complex of Isoliquiritigenin With Sulfobutyl Ether-β-Cyclodextrin: Preparation, Characterization, Inclusion Mode, Solubilization, and Stability

Abstract

Isoliquiritigenin (ISL) possesses a wide variety of pharmacological properties, however, its poor solubility and oral bioavailability pose a significant barrier to its application. In present studies, the ISL inclusion complex was prepared with sulfobutyl ether-β-cyclodextrin (SBE-β-CD). The physicochemical characterizations of ISL-SBE-β-CD were performed with Fourier transform infrared (FT-IR) spectroscopy and X-ray powder diffraction (XRD). Phase solubility study suggested a 1:1 formation of ISL-SBE-β-CD complexes. The water solubility of ISL rose from 13.6 μM to 4.05 mM by the inclusion of SBE-β-CD. The antioxidant activities (IC50) of ISL-SBE-β-CD reached 42.2 μg/ml, which was significantly lower than that of ISL (60.5 μg/ml). Its stability in biological environments was also enhanced.

Optimization, Characterization, Molecular Docking, and In Vitro Release of BBH/Lysine‐β‐cyclodextrin Inclusion Complex

“…[14a,16] Wu et al prepared the isoliquiritigenin (ISL) inclusion complex with sulfobutylether-β-CD as raw material in an aqueous solution and increased its water solubility from 13.6 μM to 4.05 mM. [17] Giri et al prepared an inclusion complex of docetaxel (DTX) and dimethyl-β-CD(DM-β-CD) by spray drying method. The results indicated that the aqueous solubility and in vitro dissolution rate of DTX/DM-β-CD IC were 76.04-and 3.55-fold than that of free DTX powder, respectively.…”